Full Press Release Details
Shareholders Vote in Favour of All Resolutions at its Annual General
DUBLIN--(BUSINESS WIRE)--July 26, 2017--ICON plc (NASDAQ:
ICLR), a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries,
today announced that all resolutions at the Annual General Meeting of
the Company (AGM) held on July 25, 2017 (which resolutions had all been
recommended by the Board) were all duly passed by shareholders. These
resolutions were set out in the Notice of the AGM sent to shareholders
dated June 23, 2017 and are available on the ICON plc website.
The final results of the voting are as follows:
| RESOLUTION NUMBER | RESOLUTION | TOTAL NUMBER OF VOTES | VOTE FOR | VOTE AGAINST | VOTE WITHHELD | ||||||
| 1.1 | To re-elect Prof. Dermot Kelleher | 45,317,741 | 44,238,348 | 1,032,397 | 46,996 | ||||||
| 1.2 | To re-elect Prof. Hugh Brady | 45,317,741 | 44,918,234 | 352,536 | 46,971 | ||||||
| 1.3 | To re-elect Ms. Mary Pendergast | 45,317,741 | 44,917,849 | 351,464 | 48,428 | ||||||
| 1.4 | To re-elect Mr. Ronan Murphy | 45,317,741 | 44,630,167 | 640,062 | 47,512 | ||||||
| 2 | To receive accounts and reports | 45,317,741 | 45,142,850 | 3,142 | 171,749 | ||||||
| 3 | To authorise the fixing of the auditors' remuneration | 45,317,741 | 41,762,920 | 3,548,967 | 5,854 | ||||||
| 4 | To authorise the Company to allot shares | 45,317,741 | 44,310,484 | 865,120 | 142,137 | ||||||
| 5** | To disapply pre-emption rights | 45,317,741 | 44,917,093 | 238,190 | 162,458 | ||||||
| 6** | To disapply pre-emption rights for funding capital investment or acquisitions | 45,317,741 | 44,918,013 | 237,460 | 162,268 | ||||||
| 7** | To authorise the Company to make market purchases of shares | 45,317,741 | 45,177,034 | 9,283 | 131,424 | ||||||
| 8** | To authorise the price range at which the Company can reissue shares it holds as treasury shares | 45,317,741 | 44,962,079 | 121,491 | 234,171 |
** Special Resolution. All resolutions are ordinary resolutions unless
This press release contains forward-looking statements. These statements
are based on management's current expectations and information currently
available, including current economic and industry conditions. These
statements are not guarantees of future performance or actual results,
and actual results, developments and business decisions may differ from
those stated in this press release. The forward-looking statements are
subject to future events, risks, uncertainties and other factors that
could cause actual results to differ materially from those projected in
the statements, including, but not limited to, the ability to enter into
new contracts, maintain client relationships, manage the opening of new
offices and offering of new services, the integration of new business
mergers and acquisitions, as well as economic and global market
conditions and other risks and uncertainties detailed from time to time
in SEC reports filed by ICON, all of which are difficult to predict and
some of which are beyond our control. For these reasons, you should not
place undue reliance on these forward-looking statements when making
investment decisions. The word "expected" and variations of such words
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 84 locations in 38 countries and
has approximately 12,300 employees. Further information is available at www.iconplc.com.
Chief Financial Officer
Vice President Corporate Finance and Investor Relations